Year: 2024

SINGAPORE, Oct. 29, 2024 (GLOBE NEWSWIRE) — UP Fintech Holding Limited (Nasdaq: TIGR) (“UP Fintech” or the “Company”), a leading online brokerage firm focusing on global investors, today announced that the underwriters of the Company’s follow-on public offering have fully exercised their option to purchase an aggregate of 2,250,000 additional American Depositary Shares (“ADSs”), each representing 15 Class A ordinary shares of the Company, from the Company at the public offering price of US$6.25 per ADS. Deutsche Bank AG, Hong Kong Branch, China International Capital Corporation Hong Kong Securities Limited and US Tiger Securities, Inc. acted as the joint bookrunners for the ADS offering. The ADS offering has been made pursuant to an automatic shelf registration statement on Form F-3 filed with the United States Securities and Exchange...

AVTL in India undertakes primary equity issue  29 October 2024, Rotterdam, the Netherlands  Today, we announce an update regarding funding in the joint venture AVTL in follow up of our press release dated 9 July 2024.  AVTL has reached an agreement for a primary equity issue to investors for an amount of INR 8.0 billion equivalent to EUR 88 million. The proceeds of the Issue are proposed to be utilised for repayment of all, or a portion, of the outstanding unsecured borrowings of AVTL and for the purpose of execution of various projects including growth projects and/or other corporate purposes relating to AVTL’s  principal business activities. The transaction represents a shareholding of 3.4% in AVTL. As a result of this transaction, Vopak’s shareholding in AVTL will be diluted from 49% to 47.3%. The expected exceptional gain for...

                                29th October 2024Announcement no. 90/2024 To NASDAQ Copenhagen A/S                                                        Jyske Realkredit’s Financial Calendar for 2025 – updated From 2025, Jyske Realkredit A/S will not publish an interim report for the 1st quarter and 1st – 3rd quarter respectively. A company announcement will be published instead. On the following dates in 2025, notification will be sent to NASDAQ Copenhagen A/S: Announcement of the 2024 results                26 February         Annual General Meeting                        24 March Company announcement for the first quarter        7 May Interim report for the first half of 2025                19 August Company announcement for the first nine months        29 October Yours faithfully, Jyske Realkredit A/S Carsten Tirsbæk MadsenCEO Please...

Oslo, Norway – October 29, 2024 – IDEX Biometrics has appointed Kristian Flaten as Chief Financial Officer, effective November 1, 2024. Kristian Flaten brings over 25 years of financial leadership and experience with international business and financing, including from Asian growth markets, a strong focus for IDEX Biometrics. He has a proven track record in corporate finance, debt financing and business development in growth companies.  Kristian has a background as CFO with Quantafuel ASA, recycling plastic waste, and as VP Corporate Finance with BW Offshore, oilfield services. Additionally, he has experience from the financial sector with Export Finance Norway and Handelsbanken.  Kristian holds a Master of Science from NHH (Norwegian School of Economics), with majors in Finance and Strategy. He will be based at IDEX Biometrics headquarters...

QIAstat-Dx Respiratory Panel Mini targets the five most actionable respiratory pathogens in outpatient settings to help clinicians make precise treatment decisions // With the new test and the 21-target QIAstat-Dx Respiratory Panel Plus, clinicians can fine-tune their diagnostic approach for individual patients, promoting better diagnostic stewardship // FDA decision marks third positive U.S. regulatory outcome for QIAstat-Dx to date in 2024 Germantown, Maryland, and Venlo, the Netherlands, Oct. 29, 2024 (GLOBE NEWSWIRE) — QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA) has cleared the QIAstat-Dx Respiratory Panel Mini test for clinical use. It is the third test to receive FDA clearance for use with QIAstat-Dx systems in 2024. The QIAstat-Dx Respiratory Panel Mini...